|
Document - Document and Entity Information |
Document - Document and Entity Information (USD $) |
12 Months Ended |
|
|
( custom:DocumentAndEntityInformationAbstract [Extension] ) |
|
|
|
|
Dec. 31, 2015 |
Jun. 30, 2015 |
Apr. 7, 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
Entity Registrant Name |
Artventive Medical Group, Inc. | |
| |
| |
( dei:EntityRegistrantName ) |
| |
| |
| |
Entity Central Index Key |
0001405249 | |
| |
| |
( dei:EntityCentralIndexKey ) |
| |
| |
| |
Document Type |
10-K | |
| |
| |
( dei:DocumentType ) |
| |
| |
| |
Document Period End Date |
2015-12-31 | |
| |
| |
( dei:DocumentPeriodEndDate ) |
| |
| |
| |
Amendment Flag |
false | |
| |
| |
( dei:AmendmentFlag ) |
| |
| |
| |
Current Fiscal Year End Date |
--12-31 | |
| |
| |
( dei:CurrentFiscalYearEndDate ) |
| |
| |
| |
Is Entity a Well-known Seasoned Issuer? |
No | |
| |
| |
( dei:EntityWellKnownSeasonedIssuer ) |
| |
| |
| |
Is Entity a Voluntary Filer? |
No | |
| |
| |
( dei:EntityVoluntaryFilers ) |
| |
| |
| |
Is Entity's Reporting Status Current? |
Yes | |
| |
| |
( dei:EntityCurrentReportingStatus ) |
| |
| |
| |
Entity Filer Category |
Smaller Reporting Company | |
| |
| |
( dei:EntityFilerCategory ) |
| |
| |
| |
Entity Public Float |
| |
42,717,207 | |
| |
( dei:EntityPublicFloat ) |
| |
| |
| |
Entity Common Stock, Shares Outstanding |
| |
| |
63,657,086 | |
( dei:EntityCommonStockSharesOutstanding ) |
| |
| |
| |
Document Fiscal Period Focus |
FY | |
| |
| |
( dei:DocumentFiscalPeriodFocus ) |
| |
| |
| |
Document Fiscal Year Focus |
2015 | |
| |
| |
( dei:DocumentFiscalYearFocus ) |
| |
| |
| |
|
(End Document - Document and Entity Information) |
|
Statement - Consolidated Balance Sheets |
Statement - Consolidated Balance Sheets (USD $) |
|
|
( us-gaap:StatementOfFinancialPositionAbstract ) |
|
|
|
Dec. 31, 2015 |
Dec. 31, 2014 |
|
|
|
|
|
|
|
|
|
|
| |
| |
|
| |
| |
|
| |
| |
|
| |
| |
Assets |
| |
| |
( us-gaap:AssetsAbstract ) |
| |
| |
current |
| |
| |
( us-gaap:AssetsCurrentAbstract ) |
| |
| |
Cash |
21,781 | |
104,030 | |
( us-gaap:Cash ) |
| |
| |
Accounts receivable |
18,118 | |
22,662 | |
( us-gaap:AccountsReceivableNet ) |
| |
| |
Prepaid expenses |
11,655 | |
1,048 | |
( us-gaap:PrepaidExpenseCurrent ) |
| |
| |
Inventory |
303,044 | |
23,738 | |
( us-gaap:InventoryGross ) |
| |
| |
Total current assets |
354,598 | |
151,478 | |
( us-gaap:AssetsCurrent ) |
| |
| |
Property, plant and equipment |
| |
| |
( us-gaap:PropertyPlantAndEquipmentAbstract ) |
| |
| |
Office equipment |
26,870 | |
17,953 | |
( us-gaap:PropertyPlantAndEquipmentOther ) |
| |
| |
Accumulated Depreciation |
(9,582 | ) |
(5,467 | ) |
( us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment ) |
| |
| |
net property, plant and equipment |
17,288 | |
12,486 | |
( us-gaap:PropertyPlantAndEquipmentNet ) |
| |
| |
OTHER ASSETS |
| |
| |
( us-gaap:OtherAssetsAbstract ) |
| |
| |
Deposits |
81,530 | |
25,007 | |
( us-gaap:Deposits ) |
| |
| |
TOTAL OTHER ASSETS |
81,530 | |
25,007 | |
( us-gaap:OtherAssets ) |
| |
| |
|
| |
| |
|
| |
| |
Total assets |
453,416 | |
188,971 | |
( us-gaap:Assets ) |
| |
| |
|
| |
| |
|
| |
| |
Liabilities and stockholders DEFICIT |
| |
| |
( us-gaap:LiabilitiesAndStockholdersEquityAbstract ) |
| |
| |
current |
| |
| |
( us-gaap:LiabilitiesCurrentAbstract ) |
| |
| |
Accounts payable |
924,089 | |
221,397 | |
( us-gaap:AccountsPayableCurrent ) |
| |
| |
Accrued expenses |
— | |
1,043,300 | |
( us-gaap:AccruedLiabilitiesCurrent ) |
| |
| |
Total current liabilities |
924,089 | |
1,264,697 | |
( us-gaap:LiabilitiesCurrent ) |
| |
| |
LONG-TERM LIABILITIES |
| |
| |
( us-gaap:LongTermDebtAbstract ) |
| |
| |
Notes payable |
500,000 | |
500,000 | |
( us-gaap:NotesPayable ) |
| |
| |
TOTAL LONG-TERM LIABILITIES |
500,000 | |
500,000 | |
( us-gaap:LongTermDebtNoncurrent ) |
| |
| |
|
| |
| |
|
| |
| |
TOTAL LIABILITIES |
1,424,089 | |
1,764,697 | |
( us-gaap:AccruedLiabilitiesCurrentAndNoncurrent ) |
| |
| |
|
| |
| |
|
| |
| |
stockholders DEFICIT |
| |
| |
( us-gaap:StockholdersEquityAbstract ) |
| |
| |
|
| |
| |
|
| |
| |
Common stock, par value $.001, 100,000,000 shares authorized, 63,592,086 and 59,506,286 shares issued and outstanding at December 31, 2015 and 2014, respectively |
63,592 | |
59,506 | |
( us-gaap:CommonStockParOrStatedValuePerShare ) |
| |
| |
Additional paid in capital |
17,028,580 | |
12,879,982 | |
( us-gaap:AdditionalPaidInCapital ) |
| |
| |
Accumulated deficit |
(18,062,845 | ) |
(14,515,214 | ) |
( us-gaap:CumulativeEarningsDeficit ) |
| |
| |
TOTAL STOCKHOLDERS DEFICIT |
(970,673 | ) |
(1,575,726 | ) |
( us-gaap:StockholdersEquity ) |
| |
| |
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT |
453,416 | |
188,971 | |
( us-gaap:LiabilitiesAndStockholdersEquity ) |
| |
| |
|
(End Statement - Consolidated Balance Sheets) |
|
Statement - Consolidated Balance Sheets (Parenthetical) |
Statement - Consolidated Balance Sheets (Parenthetical) (USD $) |
|
|
( us-gaap:StatementOfFinancialPositionAbstract ) |
|
|
|
Dec. 31, 2015 |
Dec. 31, 2014 |
|
|
|
|
|
|
|
|
|
Common stock, par value $.001, shares authorized |
100,000,000 | |
100,000,000 | |
( us-gaap:CommonStockSharesAuthorized ) |
| |
| |
Common stock, par value $.001, shares issued and outstanding |
63,592,086 | |
59,506,286 | |
( us-gaap:CommonStockSharesIssued ) |
| |
| |
|
(End Statement - Consolidated Balance Sheets (Parenthetical)) |
|
Statement - Consolidated Statements of Operations and Comprehensive Loss |
Statement - Consolidated Statements of Operations and Comprehensive Loss (USD $) |
12 Months Ended |
( us-gaap:IncomeStatementAbstract ) |
|
|
Dec. 31, 2015 |
Dec. 31, 2014 |
|
|
|
|
|
|
|
|
|
|
| |
| |
|
| |
| |
|
| |
| |
|
| |
| |
revenues |
230,154 | |
111,732 | |
( us-gaap:Revenues ) |
| |
| |
COST OF GOODS SOLD |
230,154 | |
111,732 | |
( us-gaap:CostOfGoodsSold ) |
| |
| |
GROSS PROFIT |
— | |
— | |
( us-gaap:GrossProfit ) |
| |
| |
operating expenses |
| |
| |
( us-gaap:OperatingExpensesAbstract ) |
| |
| |
Research and development |
1,608,593 | |
3,127,850 | |
( us-gaap:ResearchAndDevelopmentExpense ) |
| |
| |
Selling, general and administrative |
1,934,928 | |
3,142,652 | |
( us-gaap:SellingGeneralAndAdministrativeExpense ) |
| |
| |
Depreciation expense |
4,115 | |
3,164 | |
( us-gaap:Depreciation ) |
| |
| |
Total Expenses |
3,547,636 | |
6,273,666 | |
( us-gaap:OperatingExpenses ) |
| |
| |
Operating loss before other items and income taxes |
(3,547,636 | ) |
(6,273,666 | ) |
( us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic ) |
| |
| |
Other income |
| |
| |
( us-gaap:OtherIncomeAndExpensesAbstract ) |
| |
| |
Interest income |
5 | |
699 | |
( us-gaap:InterestAndDividendIncomeOperating ) |
| |
| |
Income taxes |
— | |
— | |
( us-gaap:IncomeTaxesPaid ) |
| |
| |
net loss availAble to common stockholders |
(3,547,631 | ) |
(6,272,967 | ) |
( us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic ) |
| |
| |
COMPREHENSIVE LOSS FOR THE PERIOD |
(3,547,631 | ) |
(6,272,967 | ) |
( us-gaap:ComprehensiveIncomeNetOfTax ) |
| |
| |
basic and diluted loss per common share |
0 | |
0 | |
( us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare ) |
| |
| |
weighted average shares outstanding |
61,701,498 | |
57,352,546 | |
( us-gaap:WeightedAverageBasicSharesOutstandingProForma ) |
| |
| |
|
(End Statement - Consolidated Statements of Operations and Comprehensive Loss) |
|
Statement - Consolidated Statements of Changes in Capital Deficiency |
Statement - Consolidated Statements of Changes in Capital Deficiency (USD $) |
|
|
|
|
( us-gaap:StatementOfStockholdersEquityAbstract ) |
|
|
|
|
|
Common Stock |
Additional Paid-In Capital |
Retained Earnings / Accumulated Deficit |
<Total> |
( us-gaap:StatementEquityComponentsAxis ) |
|
|
|
|
|
|
|
|
|
( us-gaap:EquityComponentDomain ) |
|
|
|
|
From Jan. 1, 2014 to Dec. 31, 2014 |
| |
| |
| |
| |
|
| |
| |
| |
| |
Common shares issued in private place |
4,200 | |
4,195,800 | |
| |
4,200,000 | |
( us-gaap:StockIssuedDuringPeriodValueNewIssues ) |
| |
| |
| |
| |
Common shares issued in private placement, in shares |
4,200,000 | |
| |
| |
| |
( us-gaap:StockIssuedDuringPeriodSharesNewIssues ) |
| |
| |
| |
| |
Common shares to be issued as finder's fee |
| |
(420,000 | ) |
| |
| |
( us-gaap:StockIssuedDuringPeriodValueOther ) |
| |
| |
| |
| |
Common shares to be issued as finder's fee, in shares |
| |
| |
| |
| |
( us-gaap:StockIssuedDuringPeriodSharesOther ) |
| |
| |
| |
| |
Shares isued for exercise of stock options |
| |
| |
| |
| |
( us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised ) |
| |
| |
| |
| |
Shares issued for exercise of stock optoins, in shares |
| |
| |
| |
| |
( us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities ) |
| |
| |
| |
| |
Stock options issued for services |
| |
47,903 | |
| |
47,903 | |
( us-gaap:EmployeeBenefitsAndShareBasedCompensation ) |
| |
| |
| |
| |
Loss during year |
| |
| |
(6,272,967 | ) |
| |
( us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted ) |
| |
| |
| |
| |
Balance |
59,506 | |
12,879,982 | |
(14,515,214 | ) |
(1,575,726 | ) |
( us-gaap:StockholdersEquityOther ) |
| |
| |
| |
| |
Balance, in shares |
59,506,286 | |
| |
| |
| |
( us-gaap:SharesIssued ) |
| |
| |
| |
| |
|
| |
| |
| |
| |
|
| |
| |
| |
| |
From Jan. 1, 2015 to Dec. 31, 2015 |
| |
| |
| |
| |
|
| |
| |
| |
| |
Common shares issued in private place |
3,050 | |
3,046,950 | |
| |
3,050,000 | |
( us-gaap:StockIssuedDuringPeriodValueNewIssues ) |
| |
| |
| |
| |
Common shares issued in private placement, in shares |
3,050,000 | |
| |
| |
| |
( us-gaap:StockIssuedDuringPeriodSharesNewIssues ) |
| |
| |
| |
| |
Common shares to be issued as finder's fee |
986 | |
1,004,814 | |
| |
1,005,800 | |
( us-gaap:StockIssuedDuringPeriodValueOther ) |
| |
| |
| |
| |
Common shares to be issued as finder's fee, in shares |
985,800 | |
| |
| |
| |
( us-gaap:StockIssuedDuringPeriodSharesOther ) |
| |
| |
| |
| |
Shares isued for exercise of stock options |
50 | |
| |
| |
50 | |
( us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised ) |
| |
| |
| |
| |
Shares issued for exercise of stock optoins, in shares |
50,000 | |
| |
| |
| |
( us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities ) |
| |
| |
| |
| |
Stock options issued for services |
| |
96,834 | |
| |
96,834 | |
( us-gaap:EmployeeBenefitsAndShareBasedCompensation ) |
| |
| |
| |
| |
Loss during year |
| |
| |
(3,547,631 | ) |
(3,547,631 | ) |
( us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted ) |
| |
| |
| |
| |
Balance |
63,592 | |
17,028,580 | |
(18,062,845 | ) |
(970,673 | ) |
( us-gaap:StockholdersEquityOther ) |
| |
| |
| |
| |
Balance, in shares |
63,592,086 | |
| |
| |
| |
( us-gaap:SharesIssued ) |
| |
| |
| |
| |
|
(End Statement - Consolidated Statements of Changes in Capital Deficiency) |
|
Statement - Consolidated Statements of Cash Flows |
Statement - Consolidated Statements of Cash Flows (USD $) |
12 Months Ended |
( us-gaap:StatementOfCashFlowsAbstract ) |
|
|
Dec. 31, 2015 |
Dec. 31, 2014 |
|
|
|
|
|
|
|
|
|
cash flow from operating activities |
| |
| |
( us-gaap:NetCashProvidedByUsedInOperatingActivitiesAbstract ) |
| |
| |
Net loss |
(3,547,631 | ) |
(6,272,967 | ) |
( us-gaap:NetIncomeLoss ) |
| |
| |
Adjustments to reconcile net loss to net cash used by operating activities |
| |
| |
( us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract ) |
| |
| |
|
| |
| |
|
| |
| |
Depreciation expense |
4,115 | |
3,164 | |
( us-gaap:DepreciationAndAmortization ) |
| |
| |
Issuance of common stock and options for services |
96,834 | |
47,903 | |
( us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities ) |
| |
| |
Changes in operating assets and liabilities |
| |
| |
( us-gaap:IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract ) |
| |
| |
Accounts receivable |
4,544 | |
(22,662 | ) |
( us-gaap:IncreaseDecreaseInAccountsReceivable ) |
| |
| |
Prepaid expenses |
(10,607 | ) |
8,050 | |
( us-gaap:IncreaseDecreaseInPrepaidExpense ) |
| |
| |
Inventory |
(279,306 | ) |
3,165 | |
( us-gaap:IncreaseDecreaseInInventories ) |
| |
| |
Deposits |
(56,523 | ) |
26,041 | |
( us-gaap:IncreaseDecreaseInDeposits ) |
| |
| |
Accounts payable |
702,692 | |
(51,112 | ) |
( us-gaap:IncreaseDecreaseInAccountsPayable ) |
| |
| |
Accrued expenses |
(37,500 | ) |
37,500 | |
( us-gaap:IncreaseDecreaseInAccruedLiabilities ) |
| |
| |
Net cash used by operating activities |
(3,123,382 | ) |
(6,220,918 | ) |
( us-gaap:NetCashProvidedByUsedInContinuingOperations ) |
| |
| |
cash flows from investing activities |
| |
| |
( us-gaap:NetCashProvidedByUsedInInvestingActivitiesAbstract ) |
| |
| |
Purchase of equipment |
(8,917 | ) |
(1,573 | ) |
( us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ) |
| |
| |
NET CASH used BY INVESTING ACTIVITIES |
(8,917 | ) |
(1,573 | ) |
( us-gaap:NetCashProvidedByUsedInInvestingActivities ) |
| |
| |
cash flows from financing activities |
| |
| |
( us-gaap:NetCashProvidedByUsedInFinancingActivitiesAbstract ) |
| |
| |
Issuance of common stock for cash |
3,050,050 | |
4,200,000 | |
( us-gaap:ProceedsFromIssuanceOrSaleOfEquity ) |
| |
| |
Issuance of notes payable |
— | |
500,000 | |
( us-gaap:ProceedsFromNotesPayable ) |
| |
| |
NET CASH PROVIDED BY FINANCING ACTIVITIES |
3,050,050 | |
4,700,000 | |
( us-gaap:NetCashProvidedByUsedInFinancingActivities ) |
| |
| |
net increase (decrease) in cash |
(82,249 | ) |
(1,522,491 | ) |
( us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease ) |
| |
| |
cash, beginning of period |
104,030 | |
1,626,521 | |
( us-gaap:Cash ) |
| |
| |
cash, end of period |
21,781 | |
104,030 | |
( us-gaap:Cash ) |
| |
| |
Cash paid during the year: |
| |
| |
( us-gaap:SupplementalCashFlowInformationAbstract ) |
| |
| |
Interest paid |
— | |
— | |
( us-gaap:InterestPaid ) |
| |
| |
Income taxes paid |
800 | |
— | |
( us-gaap:IncomeTaxesPaidNet ) |
| |
| |
Non-cash investing and financing activities: |
| |
| |
( us-gaap:CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract ) |
| |
| |
Transfer of stock for accrued issuance costs |
1,005,800 | |
— | |
( us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts ) |
| |
| |
Accrual of stock issuance cost |
— | |
420,000 | |
( us-gaap:PaymentsOfStockIssuanceCosts ) |
| |
| |
|
(End Statement - Consolidated Statements of Cash Flows) |
|
Disclosure - Basis of Financial Statement Presentation |
Disclosure - Basis of Financial Statement Presentation (USD $) |
12 Months Ended |
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Basis of Financial Statement Presentation |
NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION
The accompanying consolidated audited financial
statements have been prepared by ArtVentive Medical Group, Inc. and its Subsidiary, ArtVentive Medical Group, Canada Inc., (the
Company) in accordance with accounting principles generally accepted in the United States of America (U.S.
GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). The information furnished
in the financial statements includes normal recurring adjustments and reflects all adjustments, which in the opinion of management,
are necessary for a fair presentation of such financial statements.
| |
( us-gaap:BasisOfAccounting ) |
| |
|
(End Disclosure - Basis of Financial Statement Presentation) |
|
Disclosure - Organization |
Disclosure - Organization (USD $) |
12 Months Ended |
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Organization |
NOTE 2 - ORGANIZATION
The Company is a medical device company focused
on developing, manufacturing and marketing a family of endoluminal occlusion devices, known as the Endoluminal Occlusion System
(EOS). Through its patented technology, the Company has developed minimally invasive occlusion devices and procedures capable
of achieving immediate, complete, and permanent occlusion of peripheral vasculature. EOS was developed by the Company and
serves as a proprietary technology platform for several major clinical areas including peripheral and neurological vascular disorders,
women's health, interventional oncology and cardiology procedures.
The Company was incorporated on January 23,
2007. The Companys fiscal year end is December 31. To date, the Companys activities have been committed to the development
of EOS, intellectual property, animal studies, human studies, patent filings, and developing a regulatory strategy for initial
clinical indications pertinent to European, manufacturing and FDA submissions and approvals, corporate operations and the raising
of equity capital. The Company conducted the required human clinical studies during 2011 achieving 100% clinical and procedural
success, validating the safety and efficiency of the EOSTM device. The Company received its CE Mark certification for
EOS on May 30, 2013. In 2014, the Company began commercialization and commenced marketing with its European distributors.
On December 3, 2014, the Company received FDA approval for EOS for marketing and sales in the United States.
| |
( us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock ) |
| |
|
(End Disclosure - Organization) |
|
Disclosure - Significant Accounting Policies |
Disclosure - Significant Accounting Policies (USD $) |
12 Months Ended |
( AccountingPoliciesAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Significant Accounting Policies |
NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
The consolidated financial statements include
the transactions of the Company and its Subsidiary. All inter-company accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of the Companys
financial statements in conformity with accounting principles generally accepted in the United States requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Such estimates
include deferred tax assets arising as a result of the operating loss carry forwards. Actual results could differ from those estimates.
The Companys periodic filings with the SEC include, where applicable, disclosures of estimates, assumptions, uncertainties
and markets that could affect the financial statements and future operations of the Company.
Common Stock Issued for Services
Services purchased and other transactions
settled in the Companys common stock and stock options are recorded at the estimated fair value of the stock issued and
options granted if that value is more readily determinable than the fair value of the consideration received.
Earnings Per Share of Common Stock
In accordance with accounting guidance
now codified as FASB ASC Topic 260, Earnings per Share, basic earnings (loss) per share is computed by dividing net income
(loss) by weighted average number of shares of common stock outstanding during each period.
Diluted earnings (loss) per share is
computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially
dilutive securities outstanding during the period.
The Company had the following potential
common stock equivalents at December 31, 2015:
Common stock warrants |
|
3,050,000 |
Common stock options |
|
370,000 |
Total common stock equivalents |
|
3,420,000 |
Since the Company recorded net losses
in the years ended December 31, 2015 and 2014, the effect of considering any common stock equivalents, if outstanding, would have
been anti-dilutive. Therefore, a separate computation of diluted earnings (loss) per share is not presented.
The following table sets forth the computation of earnings
per share:
|
|
December 31, 2015 |
|
December 31, 2014 |
Net income (loss) |
|
$ |
(3,547,631) |
|
$ |
(6,272,967) |
Weighted average common shares outstanding |
|
|
61,701,498 |
|
|
57,352,546 |
Net (loss) per share |
|
$ |
(0.06) |
|
$ |
(0.11) |
Property and Equipment
The Company records property and equipment at cost and uses
straight-line depreciation methods over estimated useful lives of 5-7 years.
|
|
December 31, 2015 |
|
December 31, 2014 |
Computer equipment |
|
$ |
22,124 |
|
$ |
13,207 |
Office furniture |
|
|
4,746 |
|
|
4,746 |
Less: Accumulated depreciation |
|
|
(9,582) |
|
|
(5,467) |
Net property and equipment |
|
$ |
17,288 |
|
$ |
12,486 |
Inventory
The Companys inventory is valued at the lower of cost or
market using the first-in, first-out (FIFO) method. As of December 31, 2015 and 2014, all inventory consisted of finished goods.
As the Company begins its transition from the research and development
phase to production, management has estimated the cost of units sold to be equal to the revenue generated on those units. Other
direct cost that may be associated with the production of these units has been reflected in research and development expenses.
Foreign Currency Translations
The Companys functional and reporting
currency is the U.S. dollar. All transactions initiated in other currencies are translated into U.S. dollars using the exchange
rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translated into
the U.S. dollar at the rate of exchange in effect at the balance sheet date. Unrealized exchange gains and losses arising from
such transactions are deferred until realization and are included as a separate component of stockholders equity (deficit)
as a component of other comprehensive income or loss. Upon realization, the amount deferred is recognized in income in the period
when it is realized.
Cash and Cash Equivalents
Cash and cash equivalents consist principally
of funds on hand, on deposit with banks and liquid investment funds having maturity of three months or less at the time of the
purchase. The Company has no cash equivalents. The Company had funds on deposit of $21,781 as of December 31, 2015.
Receivables
The accounts receivable balance of $18,118
as of December 31, 2015 is comprised of balances due from four customers totaling $5,760, $5,568, $3,210, and $3,580. The accounts
receivable balance as of December 31, 2014 was comprised of balances from two customers. No bad debts were written off.
Revenue Recognition
Revenue for the sale of goods in the course
of the ordinary activities is measured at the fair value of the consideration received or receivable, net of returns. Revenue for
sale of goods is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of
the consideration is probable, the associated costs and possible return of the goods can be estimated reliably, there is no continuing
involvement with the goods, and the amount of revenue can be measured reliably.
Concentrations of Credit Risk
Certain financial instruments, which subject
the Company to concentration of credit risk, consist of cash and accounts receivable. The Company maintains cash balances at financial
institutions, which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits of $250,000. As of December
31, 2015, the Company had no deposits in excess of federally insured limits in its U.S. bank. The Company has not experienced any
losses with regard to its bank accounts and believes it is not exposed to any risk of loss on its cash in bank accounts. As of
December 31, 2015, four customers represented 100% (31.8%, 30.7%, 17.7% and 19.8%) of our accounts receivable.
As of December 31, 2015, Medical Murray, accounted
for more than 10% of our purchases and accounts payable.
| |
( us-gaap:SignificantAccountingPoliciesTextBlock ) |
| |
|
(End Disclosure - Significant Accounting Policies) |
|
Disclosure - Notes Payable |
Disclosure - Notes Payable (USD $) |
12 Months Ended |
( DebtDisclosureAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Notes Payable |
NOTE 4 NOTES PAYABLE
On April 1, 2014, the Company borrowed $250,000
from an unrelated party and issued a note payable due on or before December 31, 2014, with interest at 3% per annum. On December
31, 2014, the Company and the lender executed an extension of the note, which is due on or before December 31, 2017. The interest
remains at 3%. The lender may convert all or part of the debt, including interest, into common stock of the Company at any time
at the rate of $1.00 per share.
On April 1, 2014, the Company borrowed $250,000
from an unrelated party and issued a note payable due on or before December 31, 2014, with interest at 3% per annum. On December
31, 2014, the Company and the lender executed an extension of the note, which is due on or before December 31, 2017. The interest
remains at 3%. The lender may convert all of part of the debt, including interest, into common stock of the Company at any time
at the rate of $1.00 per share.
Long-term debt consists of the following:
|
|
|
December 31,
2015 |
|
|
December 31,
2014 |
Note payable to a private party, interest at 3.0%,
interest and principal due December 31, 2017 |
|
$ |
250,000 |
|
$ |
250,000 |
Note payable to a private party, interest at 3.0%,
interest and principal due December 31, 2017 |
|
|
250,000 |
|
|
250,000 |
Total |
|
|
500,000 |
|
|
500,000 |
Less: Current maturities of long-term debt |
|
|
- |
|
|
- |
Long-term debt |
|
$ |
500,000 |
|
$ |
500,000 |
Maturities on long-term debt are as follows:
2016 |
|
$ |
- |
2017 |
|
|
500,000 |
|
|
$ |
500,000 |
| |
( us-gaap:DebtDisclosureTextBlock ) |
| |
|
(End Disclosure - Notes Payable) |
|
Disclosure - Stockholders Equity |
Disclosure - Stockholders Equity (USD $) |
12 Months Ended |
( EquityAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Stockholders Equity |
NOTE 5 - STOCKHOLDERS EQUITY
Effective April 22, 2008, the Company forward-split
its issued common stock on a ratio of 5.8 shares for each original share. As a result of this transaction, 11,078,000 shares were
issued. Effective February 12, 2010, the Company forward-split its issued common stock on a ratio of 1.65 shares for each one prior
share. As a result of this transaction, 8,442,200 shares were issued. Consideration for the issue of additional shares has been
charged against additional paid in capital. The forward stock splits adjustments have been applied retroactively.
Stock issuances in private placements during
the years ended December 31, 2014 and 2015 are as follows:
Stock Issuance Date |
|
Common
Shares |
|
|
Proceeds
Received |
|
|
|
|
|
|
January 7, 2014 |
|
400,000 |
|
$ |
400,000 |
February 11, 2014 |
|
400,000 |
|
|
400,000 |
March 6, 2014 |
|
300,000 |
|
|
300,000 |
May 23, 2014 |
|
100,000 |
|
|
100,000 |
June 24, 2014 |
|
1,000,000 |
|
|
1,000,000 |
July 23, 2014 |
|
500,000 |
|
|
500,000 |
August 29, 2014 |
|
250,000 |
|
|
250,000 |
September 29, 2014 |
|
150,000 |
|
|
150,000 |
September 30, 2014 |
|
100,000 |
|
|
100,000 |
October 15, 2014 |
|
100,000 |
|
|
100,000 |
November 7, 2014 |
|
80,000 |
|
|
80,000 |
November 28, 2014 |
|
70,000 |
|
|
70,000 |
December 4, 2014 |
|
250,000 |
|
|
250,000 |
December 15, 2014 |
|
250,000 |
|
|
250,000 |
December 29, 2014 |
|
250,000 |
|
|
250,000 |
|
|
|
|
|
|
Total for Year Ended 2014 |
|
4,200,000 |
|
$ |
4,200,000 |
|
|
|
|
|
|
January 23, 2015 |
|
250,000 |
|
$ |
250,000 |
February 27, 2015 |
|
150,000 |
|
|
150,000 |
March 15, 2015 |
|
100,000 |
|
|
100,000 |
March 31, 2015 |
|
150,000 |
|
|
150,000 |
April 23, 2015 |
|
150,000 |
|
|
150,000 |
May 4, 2015 |
|
100,000 |
|
|
100,000 |
May 29, 2015 |
|
500,000 |
|
|
500,000 |
June 1 2015 |
|
500,000 |
|
|
500,000 |
July 17, 2015 |
|
200,000 |
|
|
200,000 |
August 8, 2015 |
|
50,000 |
|
|
50,000 |
August 27, 2015 |
|
300,000 |
|
|
300,000 |
September 28, 2015 |
|
250,000 |
|
|
250,000 |
October 26, 2015 |
|
150,000 |
|
|
150,000 |
November 20, 2015 |
|
100,000 |
|
|
100,000 |
December 12, 2015 |
|
100,000 |
|
|
100,000 |
|
|
|
|
|
|
Total for Year Ended 2015 |
|
3,050,000 |
|
$ |
3,050,000 |
On May 5, 2015, 980,800 shares were issued
for services rendered valued at $980,800.
On August 12, 2015, 25,000 shares were issued
for services rendered valued at $25,000.
| |
( us-gaap:StockholdersEquityNoteDisclosureTextBlock ) |
| |
|
(End Disclosure - Stockholders Equity) |
|
Disclosure - Going Concern and Liquidty Consideration |
Disclosure - Going Concern and Liquidty Consideration (USD $) |
12 Months Ended |
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Going Concern and Liquidty Consideration |
NOTE 6 - GOING CONCERN AND LIQUIDITY CONSIDERATIONS
The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization
of assets and satisfaction of liabilities in the normal course of business. As of December 31, 2015, the Company had a negative
working capital balance of $569,491 and an accumulated deficit of $18,062,845. These factors raise substantial doubt about the
Company's ability to continue as a going concern. Management is in the process of evaluating various financing alternatives for
operations, as the Company will need to finance future research and development activities and general and administrative expenses
through fund raising in the public or private equity markets. Management believes that it will be able to secure the necessary
financing as a result of ongoing financing discussions with third party investors and existing shareholders. However, there is
no assurance that the Company will be successful with those initiatives, and it does not have any firm commitments from investors
at this time.
| |
( us-gaap:LiquidityDisclosureTextBlock ) |
| |
|
(End Disclosure - Going Concern and Liquidty Consideration) |
|
Disclosure - Recently Issued Accounting Pronouncements |
Disclosure - Recently Issued Accounting Pronouncements (USD $) |
12 Months Ended |
( AccountingChangesAndErrorCorrectionsAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Recently Issued Accounting Pronouncements |
NOTE
7 - recently issued accounting pronouncements
The Company has reviewed Accounting
Standards Update (ASU) through ASU No. 2016-09 which contain technical corrections to existing guidance or affect
guidance to specialized industries or entities. These updates have no current applicability to the Company or their effect on the
financial statements would not have been significant.
| |
( us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock ) |
| |
|
(End Disclosure - Recently Issued Accounting Pronouncements) |
|
Disclosure - Provisions for Income Taxes |
Disclosure - Provisions for Income Taxes (USD $) |
12 Months Ended |
( IncomeTaxDisclosureAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Provisions for Income Taxes |
note
8 - provision for income taxes
The Company recognizes the tax effects of transactions
in the year in which such transactions enter into the determination of net income, regardless of when reported for tax purposes.
Deferred taxes are provided in the financial statements under ASC Topic 740, Income Taxes, to give effect to the resulting
temporary differences which may arise from differences in the bases of fixed assets, depreciation methods, allowances, and start-up
costs based on the income taxes expected to be payable in future years. Exploration and development stage deferred tax assets arising
as a result of net operating loss carry forwards have been offset completely by a valuation allowance due to the uncertainty of
their utilization in future periods. Tax operating loss carry forwards generated during the period from January 23, 2007 (date
of inception) through December 31, 2015 of approximately $17.8 million will begin to expire in 2027. Accordingly, deferred tax
assets of approximately $7,425,791 (2014 $6,074,247) related to net operating loss carryforwards and $192,461 related to
stock-based compensation were offset in full by the valuation allowance.
The Company has no tax positions at December
31, 2015 and 2014 for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of
such deductibility.
The Companys tax returns for the years
ended December 31, 2015, 2014, 2013 and 2012 are open for examination under Federal Statute of Limitations and for the years ended
December 31, 2015, 2014 and 2013 under the State of California Statute of Limitations.
The Company recognizes interest accrued related
to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company had no accruals for interest
and penalties since inception.
A reconciliation of the provision for income
tax expense with the expected income tax computed by applying the federal statutory income tax to income before provision for income
taxes is as follows:
|
|
|
Years Ended December 31, |
|
|
|
2015 |
|
|
2014 |
Income tax (benefit) computed at |
|
|
|
|
|
|
Federal statutory tax rate of 34% |
|
$ |
(1,206,195) |
|
$ |
(2,132,809) |
Change in valuation allowance |
|
|
1,519,806 |
|
|
2,687,339 |
State taxes (net of federal benefit) |
|
|
(313,611) |
|
|
(554,530) |
|
|
$ |
- |
|
$ |
- |
| |
( us-gaap:IncomeTaxDisclosureTextBlock ) |
| |
|
(End Disclosure - Provisions for Income Taxes) |
|
Disclosure - Warrants and Options |
Disclosure - Warrants and Options (USD $) |
12 Months Ended |
( OtherLiabilitiesDisclosureAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Warrants and Options |
NOTE 9 - WARRANTS
AND OPTIONS
During the year ended December 31, 2015, the
Company granted 3,050,000 warrants to purchase shares of Common Stock of which all have a 1-year exercise term. The Company valued
these warrants utilizing a Black-Scholes option-pricing model and the fair value was recorded in additional paid-in capital.
The following is a summary of the Companys
warrant activity as of December 31, 2015:
|
|
Warrants |
|
|
Weighted
Average
Exercise
Price |
Outstanding - December 31, 2013 |
|
4,358,000 |
|
$ |
1.50 |
Granted - 2014 |
|
4,200,000 |
|
|
1.50 |
Exercised - 2014 |
|
- |
|
|
- |
Forfeited - 2014 |
|
(4,358,000) |
|
|
1.50 |
Outstanding December 31, 2014 |
|
4,200,000 |
|
$ |
1.50 |
Exercisable December 31, 2014 |
|
4,200,000 |
|
$ |
1.50 |
|
|
|
|
|
|
Granted - 2015 |
|
3,050,000 |
|
$ |
1.50 |
Exercised - 2015 |
|
- |
|
|
- |
Forfeited - 2015 |
|
(4,200,000) |
|
$ |
1.50 |
Outstanding December 31, 2015 |
|
3,050,000 |
|
$ |
1.50 |
Exercisable December 31, 2015 |
|
3,050,000 |
|
$ |
1.50 |
Warrants outstanding and exercisable at December
31, 2015 are as follows:
Warrants Outstanding |
|
Warrants Exercisable |
|
Exercise
Price |
|
Number
Outstanding |
|
Weighted
Average
Remaining
Contractual
Life (in Years) |
|
Weighted
Average
Exercise Price |
|
|
Number
Exercisable |
|
|
Weighted
Average
Exercise Price |
$ |
1.50 |
|
250,000 |
|
0.02 years |
|
$ |
1.50 |
|
|
|
250,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
150,000 |
|
0.16 years |
|
$ |
1.50 |
|
|
|
150,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
100,000 |
|
0.20 years |
|
$ |
1.50 |
|
|
|
100,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
150,000 |
|
0.25 years |
|
$ |
1.50 |
|
|
|
150,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
50,000 |
|
0.29 years |
|
$ |
1.50 |
|
|
|
50,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
150,000 |
|
0.31 years |
|
$ |
1.50 |
|
|
|
150,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
100,000 |
|
0.34 years |
|
$ |
1.50 |
|
|
|
100,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
500,000 |
|
0.40 years |
|
$ |
1.50 |
|
|
|
500,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
500,000 |
|
0.42 years |
|
$ |
1.50 |
|
|
|
500,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
200,000 |
|
0.54 years |
|
$ |
1.50 |
|
|
|
200,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
300,000 |
|
0.65 years |
|
$ |
1.50 |
|
|
|
300,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
250,000 |
|
0.74 years |
|
$ |
1.50 |
|
|
|
250,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
150,000 |
|
0.82 years |
|
$ |
1.50 |
|
|
|
150,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
100,000 |
|
0.89 years |
|
$ |
1.50 |
|
|
|
100,000 |
|
|
$ |
1.50 |
$ |
1.50 |
|
100,000 |
|
0.95 years |
|
$ |
1.50 |
|
|
|
100,000 |
|
|
$ |
1.50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant activity is as follows:
Warrants issued during 2014, totaling 4,200,000,
expired during 2015.
Effective January 3, 2015, 250,000 warrants
were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the
warrants expire in 1 year.
Effective January 30, 2015, 150,000 warrants
were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the
warrants expire in 1 year.
Effective March 15, 2015, 100,000 warrants
were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the
warrants expire in 1 year.
Effective March 31, 2015, 150,000 warrants
were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the
warrants expire in 1 year.
Effective April 16, 2015, 50,000 warrants were
issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants
expire in 1 year.
Effective April 23, 2015, 150,000 warrants
were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the
warrants expire in 1 year.
Effective May 4, 2015, 100,000 warrants were
issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants
expire in 1 year.
Effective May 28, 2015, 500,000 warrants were
issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants
expire in 1 year.
Effective June 1, 2015, 500,000 warrants were
issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants
expire in 1 year.
Effective July 17, 2015, 200,000 warrants were
issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the warrants
expire in 1 year.
Effective August 12, 2015, 25,000 warrants
were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the
warrants expire in 1 year.
Effective August 27, 2015, 300,000 warrants
were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the
warrants expire in 1 year.
Effective September 28, 2015, 250,000 warrants
were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the
warrants expire in 1 year.
Effective October 26, 2015, 150,000 warrants
were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the
warrants expire in 1 year.
Effective November 20, 2015, 100,000 warrants
were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the
warrants expire in 1 year.
Effective December 12, 2015, 100,000 warrants
were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period, and the
warrants expire in 1 year.
The following is a summary of the Companys stock options
activity:
|
|
Options |
|
|
Weighted
Average
Exercise
Price |
Granted - 2014 |
|
- |
|
$ |
- |
Exercised - 2014 |
|
- |
|
|
- |
Forfeited - 2014 |
|
- |
|
|
- |
Outstanding December 31, 2014 |
|
305,000 |
|
$ |
0.836 |
Exercisable December 31, 2014 |
|
155,000 |
|
$ |
0.678 |
|
|
|
|
|
|
Granted - 2015 |
|
265,000 |
|
$ |
1.00 |
Exercised - 2015 |
|
(50,000) |
|
|
0.001 |
Forfeited - 2015 |
|
(150,000) |
|
|
1.00 |
Outstanding December 31, 2015 |
|
370,000 |
|
$ |
1.00 |
Exercisable December 31, 2015 |
|
230,000 |
|
$ |
1.00 |
Options outstanding and exercisable at December
31, 2015 are as follows:
Options Outstanding |
|
Options Exercisable |
|
|
Range of
Exercise
Price |
|
Number
Outstanding |
|
Weighted Average
Remaining
Contractual
Life (in Years) |
|
Weighted
Average
Exercise Price |
|
|
Number
Exercisable |
|
|
Weighted
Average
Exercise Price |
|
$ |
1.00 |
|
35,000 |
|
2.09 years |
|
$ |
1.00 |
|
|
|
35,000 |
|
|
$ |
1.00 |
|
$ |
1.00 |
|
10,000 |
|
2.16 years |
|
$ |
1.00 |
|
|
|
10,000 |
|
|
$ |
1.00 |
|
$ |
1.00 |
|
10,000 |
|
2.99 years |
|
$ |
1.00 |
|
|
|
10,000 |
|
|
$ |
1.00 |
|
$ |
1.00 |
|
50,000 |
|
7.92 years |
|
$ |
1.00 |
|
|
|
50,000 |
|
|
$ |
1.00 |
|
$ |
1.00 |
|
10,000 |
|
9.06 years |
|
$ |
1.00 |
|
|
|
10,000 |
|
|
$ |
1.00 |
|
$ |
1.00 |
|
100,000 |
|
9.33 years |
|
$ |
1.00 |
|
|
|
100,000 |
|
|
$ |
1.00 |
|
$ |
1.00 |
|
40,000 |
|
9.45 years |
|
$ |
1.00 |
|
|
|
- |
|
|
$ |
1.00 |
|
$ |
1.00 |
|
15,000 |
|
9.66 years |
|
$ |
1.00 |
|
|
|
15,000 |
|
|
$ |
1.00 |
|
$ |
1.00 |
|
100,000 |
|
9.73 years |
|
$ |
1.00 |
|
|
|
- |
|
|
$ |
1.00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Companys stock option activity is
as follows:
Effective November 2, 2010, the Board of Directors
of the Company granted 50,000 non-statutory stock options to a current consultant at an exercise price of $.001 per share with
the vesting date of November 2, 2013 and an expiration date of November 2, 2016. These options were exercised on August 7, 2015.
Effective February 1, 2013, the Board of Directors
of the Company granted 20,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with
the vesting date of February 1, 2013 and an expiration date of February 1, 2018.
Effective February 1, 2013, the Board of Directors
of the Company granted 5,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with the
vesting date of February 1 2013 and an expiration date of February 1, 2018.
Effective February 1, 2013, the Board of Directors
of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with
the vesting date of February 1 2013 and an expiration date of February 1, 2018.
Effective March 1, 2013, the Board of Directors
of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with
the vesting date of March 1, 2013 and an expiration date of March 1, 2018.
Effective December 27, 2013, the Board of Directors
of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with
the vesting date of December 27, 2013, and an expiration date of December 27, 2018.
Effective January 1, 2015, the Board of Directors
of the Company granted 200,000 non-statutory stock options to a then current employee at an exercise price of $1.00 per share with
50,000 of the shares vested on January 1, 2016 and the additional 75% of the shares exercisable on each of the next succeeding
three anniversaries of January 1. The 50,000 vested stock options remain outstanding, while the 150,000 non-vested options were
forfeited through a voluntary resignation on September 4, 2015.
Effective January 23, 2015, the Board of Directors
of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with
the vesting date of January 23, 2015, and an expiration date of January 23, 2025.
Effective April 30, 2015, the Board of Directors
of the Company granted 100,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with
the vesting date of April 30, 2015, and an expiration date of April 30, 2025.
Effective June 15, 2015, the Board of Directors
of the Company granted 40,000 non-statutory stock options to a current employee at an exercise price of $1.00 per share with 25%
of the shares exercisable on June 15, 2016 and an additional 25% exercisable on each of the next succeeding three anniversaries
of June 15, on a cumulative basis, so that the option, or any unexercised portion, shall be fully exercisable on and after June
15, 2019. The stock options have an expiration date of June 15, 2025.
Effective August 28, 2015, the Board of Directors
of the Company granted 15,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share with
the vesting date of August 28, 2015, and an expiration date of August 28, 2025.
Effective September 22, 2015, the Board of
Directors granted 100,000 stock options deemed an Incentive Stock Option (ISO) to a current employee, at an exercise price of $1.00
per share with 25% exercisable on September 22, 2016; and an additional 25% exercisable on each of the next succeeding three anniversaries
of September 22nd, on a cumulative basis, so that the Option, or any unexercised portion, shall be fully exercisable on and after
September 22, 2019. The stock options have an expiration date of September 22, 2025.
The Company valued these options utilizing
a Black-Scholes option-pricing model and the fair value was recorded in additional paid-in capital.
| |
( us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock ) |
| |
|
(End Disclosure - Warrants and Options) |
|
Disclosure - Subsequent Events |
Disclosure - Subsequent Events (USD $) |
12 Months Ended |
( SubsequentEventsAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Subsequent Events |
NOTE
10 - subsequent events
The Company evaluated all events or transactions
that occurred after December 31, 2015, up through the date these consolidated financial statements were issued.
Effective January 19, 2016, the Company issued
15,000 shares of common stock in a private placement for the receipt of $15,000.
Effective January 19, 2016, the Company issued
a warrant for the purchase of 15,000 shares of common stock at an exercise price of $1.50. There is no vesting period, and the
warrants expire in one year.
Effective March 1, 2016, the Company entered
into an agreement with a consultant for accounting services and issued 50,000 common shares.
| |
( us-gaap:SubsequentEventsTextBlock ) |
| |
|
(End Disclosure - Subsequent Events) |
|
Disclosure - Significant Accounting Policies (Policies) |
Disclosure - Significant Accounting Policies (Policies) (USD $) |
12 Months Ended |
( AccountingPoliciesAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Principles of Consolidation |
Principles of Consolidation
The consolidated financial statements include
the transactions of the Company and its Subsidiary. All inter-company accounts and transactions have been eliminated in consolidation. | |
( us-gaap:ConsolidationPolicyTextBlock ) |
| |
Use of Estimates |
Use of Estimates
The preparation of the Companys
financial statements in conformity with accounting principles generally accepted in the United States requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Such estimates
include deferred tax assets arising as a result of the operating loss carry forwards. Actual results could differ from those estimates.
The Companys periodic filings with the SEC include, where applicable, disclosures of estimates, assumptions, uncertainties
and markets that could affect the financial statements and future operations of the Company. | |
( us-gaap:UseOfEstimates ) |
| |
Common Stock Issued for Services |
Common Stock Issued for Services
Services purchased and other transactions
settled in the Companys common stock and stock options are recorded at the estimated fair value of the stock issued and
options granted if that value is more readily determinable than the fair value of the consideration received. | |
( us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy ) |
| |
Earnings Per Share of Common Stock |
Earnings Per Share of Common Stock
In accordance with accounting guidance
now codified as FASB ASC Topic 260, Earnings per Share, basic earnings (loss) per share is computed by dividing net income
(loss) by weighted average number of shares of common stock outstanding during each period.
Diluted earnings (loss) per share is
computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents and potentially
dilutive securities outstanding during the period.
The Company had the following potential
common stock equivalents at December 31, 2015:
Common stock warrants |
|
3,050,000 |
Common stock options |
|
370,000 |
Total common stock equivalents |
|
3,420,000 |
Since the Company recorded net losses
in the years ended December 31, 2015 and 2014, the effect of considering any common stock equivalents, if outstanding, would have
been anti-dilutive. Therefore, a separate computation of diluted earnings (loss) per share is not presented.
The following table sets forth the computation of earnings
per share:
|
|
December 31, 2015 |
|
December 31, 2014 |
Net income (loss) |
|
$ |
(3,547,631) |
|
$ |
(6,272,967) |
Weighted average common shares outstanding |
|
|
61,701,498 |
|
|
57,352,546 |
Net (loss) per share |
|
$ |
(0.06) |
|
$ |
(0.11) |
| |
( us-gaap:EarningsPerSharePolicyTextBlock ) |
| |
Property and Equipment |
Property and Equipment
The Company records property and equipment at cost and uses
straight-line depreciation methods over estimated useful lives of 5-7 years.
|
|
December 31, 2015 |
|
December 31, 2014 |
Computer equipment |
|
$ |
22,124 |
|
$ |
13,207 |
Office furniture |
|
|
4,746 |
|
|
4,746 |
Less: Accumulated depreciation |
|
|
(9,582) |
|
|
(5,467) |
Net property and equipment |
|
$ |
17,288 |
|
$ |
12,486 |
| |
( us-gaap:PropertyPlantAndEquipmentPolicyTextBlock ) |
| |
Inventory |
Inventory
The Companys inventory is valued at the lower of cost or
market using the first-in, first-out (FIFO) method. As of December 31, 2015 and 2014, all inventory consisted of finished goods.
As the Company begins its transition from the research and development
phase to production, management has estimated the cost of units sold to be equal to the revenue generated on those units. Other
direct cost that may be associated with the production of these units has been reflected in research and development expenses. | |
( us-gaap:InventoryPolicyTextBlock ) |
| |
Foreign Currency Translations |
Foreign Currency Translations
The Companys functional and reporting
currency is the U.S. dollar. All transactions initiated in other currencies are translated into U.S. dollars using the exchange
rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translated into
the U.S. dollar at the rate of exchange in effect at the balance sheet date. Unrealized exchange gains and losses arising from
such transactions are deferred until realization and are included as a separate component of stockholders equity (deficit)
as a component of other comprehensive income or loss. Upon realization, the amount deferred is recognized in income in the period
when it is realized. | |
( us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock ) |
| |
Cash and Cash Equivalents |
Cash and Cash Equivalents
Cash and cash equivalents consist principally
of funds on hand, on deposit with banks and liquid investment funds having maturity of three months or less at the time of the
purchase. The Company has no cash equivalents. The Company had funds on deposit of $21,781 as of December 31, 2015. | |
( us-gaap:CashAndCashEquivalentsPolicyTextBlock ) |
| |
Receivables |
Receivables
The accounts receivable balance of $18,118
as of December 31, 2015 is comprised of balances due from four customers totaling $5,760, $5,568, $3,210, and $3,580. The accounts
receivable balance as of December 31, 2014 was comprised of balances from two customers. No bad debts were written off. | |
( us-gaap:PolicyLoansReceivablePolicy ) |
| |
Revenue Recognition |
Revenue Recognition
Revenue for the sale of goods in the course
of the ordinary activities is measured at the fair value of the consideration received or receivable, net of returns. Revenue for
sale of goods is recognized when the significant risks and rewards of ownership have been transferred to the buyer, recovery of
the consideration is probable, the associated costs and possible return of the goods can be estimated reliably, there is no continuing
involvement with the goods, and the amount of revenue can be measured reliably. | |
( us-gaap:RevenueRecognitionPolicyTextBlock ) |
| |
Concentrations of Credit Risk |
Concentrations of Credit Risk
Certain financial instruments, which subject
the Company to concentration of credit risk, consist of cash and accounts receivable. The Company maintains cash balances at financial
institutions, which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits of $250,000. As of December
31, 2015, the Company had no deposits in excess of federally insured limits in its U.S. bank. The Company has not experienced any
losses with regard to its bank accounts and believes it is not exposed to any risk of loss on its cash in bank accounts. As of
December 31, 2015, four customers represented 100% (31.8%, 30.7%, 17.7% and 19.8%) of our accounts receivable.
As of December 31, 2015, Medical Murray, accounted
for more than 10% of our purchases and accounts payable. | |
( us-gaap:ConcentrationRiskCreditRisk ) |
| |
|
(End Disclosure - Significant Accounting Policies (Policies)) |
|
Disclosure - Significant Accounting Policies (Tables) |
Disclosure - Significant Accounting Policies (Tables) (USD $) |
12 Months Ended |
( AccountingPoliciesAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Computation of Earnings Per Share |
|
|
December 31, 2015 |
|
December 31, 2014 |
Net income (loss) |
|
$ |
(3,547,631) |
|
$ |
(6,272,967) |
Weighted average common shares outstanding |
|
|
61,701,498 |
|
|
57,352,546 |
Net (loss) per share |
|
$ |
(0.06) |
|
$ |
(0.11) |
| |
( us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock ) |
| |
Schedule of Property and Equipment |
|
|
December 31, 2015 |
|
December 31, 2014 |
Computer equipment |
|
$ |
22,124 |
|
$ |
13,207 |
Office furniture |
|
|
4,746 |
|
|
4,746 |
Less: Accumulated depreciation |
|
|
(9,582) |
|
|
(5,467) |
Net property and equipment |
|
$ |
17,288 |
|
$ |
12,486 |
| |
( us-gaap:PropertyPlantAndEquipmentScheduleOfSignificantAcquisitionsAndDisposalsTextBlock ) |
| |
|
(End Disclosure - Significant Accounting Policies (Tables)) |
|
Disclosure - Notes Payable (Tables) |
Disclosure - Notes Payable (Tables) (USD $) |
12 Months Ended |
( DebtDisclosureAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Long Term Debt |
|
|
|
December 31,
2015 |
|
|
December 31,
2014 |
Note payable to a private party, interest at 3.0%,
interest and principal due December 31, 2017 |
|
$ |
250,000 |
|
$ |
250,000 |
Note payable to a private party, interest at 3.0%,
interest and principal due December 31, 2017 |
|
|
250,000 |
|
|
250,000 |
Total |
|
|
500,000 |
|
|
500,000 |
Less: Current maturities of long-term debt |
|
|
- |
|
|
- |
Long-term debt |
|
$ |
500,000 |
|
$ |
500,000 |
| |
( us-gaap:ScheduleOfDebtInstrumentsTextBlock ) |
| |
|
(End Disclosure - Notes Payable (Tables)) |
|
Disclosure - Provisions for Income Taxes (Tables) |
Disclosure - Provisions for Income Taxes (Tables) (USD $) |
12 Months Ended |
( IncomeTaxDisclosureAbstract ) |
|
|
Dec. 31, 2015 |
|
|
|
|
|
|
Income Tax Benefit and Expense |
|
|
|
Years Ended December 31, |
|
|
|
2015 |
|
|
2014 |
Income tax (benefit) computed at |
|
|
|
|
|
|
Federal statutory tax rate of 34% |
|
$ |
(1,206,195) |
|
$ |
(2,132,809) |
Change in valuation allowance |
|
|
1,519,806 |
|
|
2,687,339 |
State taxes (net of federal benefit) |
|
|
(313,611) |
|
|
(554,530) |
|
|
$ |
- |
|
$ |
- |
| |
( us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock ) |
| |
|
(End Disclosure - Provisions for Income Taxes (Tables)) |
|
Disclosure - Going Concern and Liquidty Consideration (Details Narrative) |
Disclosure - Going Concern and Liquidty Consideration (Details Narrative) (USD $) |
|
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract ) |
|
|
|
|
|
|
|
|
|
Accumulted Deficit |
$18,062,845. | |
( us-gaap:RetainedEarningsAccumulatedDeficit ) |
| |
|
(End Disclosure - Going Concern and Liquidty Consideration (Details Narrative)) |
Contexts |
ID |
Period |
CIK |
Dimensions |
From2015-01-01to2015-12-31 |
2015-01-01 - 2015-12-31 |
0001405249 |
|
AsOf2015-06-30 |
2015-06-30 |
0001405249 |
|
AsOf2016-04-07 |
2016-04-07 |
0001405249 |
|
AsOf2015-12-31 |
2015-12-31 |
0001405249 |
|
AsOf2014-12-31 |
2014-12-31 |
0001405249 |
|
From2014-01-01to2014-12-31 |
2014-01-01 - 2014-12-31 |
0001405249 |
|
From2014-01-01to2014-12-31_us-gaap_CommonStockMember |
2014-01-01 - 2014-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:CommonStockMember |
From2015-01-01to2015-12-31_us-gaap_CommonStockMember |
2015-01-01 - 2015-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:CommonStockMember |
AsOf2013-12-31_us-gaap_CommonStockMember |
2013-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:CommonStockMember |
AsOf2014-12-31_us-gaap_CommonStockMember |
2014-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:CommonStockMember |
AsOf2015-12-31_us-gaap_CommonStockMember |
2015-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:CommonStockMember |
From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember |
2014-01-01 - 2014-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:AdditionalPaidInCapitalMember |
From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember |
2015-01-01 - 2015-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:AdditionalPaidInCapitalMember |
AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember |
2013-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:AdditionalPaidInCapitalMember |
AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember |
2014-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:AdditionalPaidInCapitalMember |
AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember |
2015-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:AdditionalPaidInCapitalMember |
From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember |
2014-01-01 - 2014-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:RetainedEarningsMember |
From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember |
2015-01-01 - 2015-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:RetainedEarningsMember |
AsOf2013-12-31_us-gaap_RetainedEarningsMember |
2013-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:RetainedEarningsMember |
AsOf2014-12-31_us-gaap_RetainedEarningsMember |
2014-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:RetainedEarningsMember |
AsOf2015-12-31_us-gaap_RetainedEarningsMember |
2015-12-31 |
0001405249 |
us-gaap:StatementEquityComponentsAxis: us-gaap:RetainedEarningsMember |
AsOf2013-12-31 |
2013-12-31 |
0001405249 |
|
|
(End Contexts) |
|
Elements |
|
|
|
|
|
|
|
|
|
Element |
Data Type |
Period Type |
Balance Type |
Custom |
AccountingChangesAndErrorCorrectionsAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
AccountingPoliciesAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
DebtDisclosureAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
EquityAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
IncomeTaxDisclosureAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
OtherLiabilitiesDisclosureAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
SubsequentEventsAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
custom:DocumentAndEntityInformationAbstract |
xbrli:stringItemType |
| Duration |
| |
| Yes (Auto) |
|
|
|
dei:AmendmentFlag |
xbrli:booleanItemType |
| Duration |
| |
| |
|
If the value is true, then the document is an amendment to previously-filed/accepted document. |
|
dei:CurrentFiscalYearEndDate |
xbrli:gMonthDayItemType |
| Duration |
| |
| |
|
End date of current fiscal year in the format --MM-DD. |
|
dei:DocumentFiscalPeriodFocus |
dei:fiscalPeriodItemType |
| Duration |
| |
| |
|
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. |
|
dei:DocumentFiscalYearFocus |
xbrli:gYearItemType |
| Duration |
| |
| |
|
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. |
|
dei:DocumentPeriodEndDate |
xbrli:dateItemType |
| Duration |
| |
| |
|
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD. |
|
dei:DocumentType |
dei:submissionTypeItemType |
| Duration |
| |
| |
|
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other". |
|
dei:EntityCentralIndexKey |
dei:centralIndexKeyItemType |
| Duration |
| |
| |
|
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. |
|
dei:EntityCommonStockSharesOutstanding |
xbrli:sharesItemType |
| Instant |
| |
| |
|
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. |
|
dei:EntityCurrentReportingStatus |
dei:yesNoItemType |
| Duration |
| |
| |
|
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. |
|
dei:EntityFilerCategory |
dei:filerCategoryItemType |
| Duration |
| |
| |
|
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. |
|
dei:EntityPublicFloat |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K. |
|
dei:EntityRegistrantName |
xbrli:normalizedStringItemType |
| Duration |
| |
| |
|
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. |
|
dei:EntityVoluntaryFilers |
dei:yesNoItemType |
| Duration |
| |
| |
|
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. |
|
dei:EntityWellKnownSeasonedIssuer |
dei:yesNoItemType |
| Duration |
| |
| |
|
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. |
|
us-gaap:AccountsPayableCurrent |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
|
us-gaap:AccountsReceivableNet |
xbrli:monetaryItemType |
| Instant |
| Debit |
| |
|
For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. |
|
us-gaap:AccruedLiabilitiesCurrent |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
|
us-gaap:AccruedLiabilitiesCurrentAndNoncurrent |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. |
|
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. |
|
us-gaap:AdditionalPaidInCapital |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. |
|
us-gaap:AdditionalPaidInCapitalMember |
nonnum:domainItemType |
| Duration |
| |
| |
|
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. |
|
us-gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all noncash expenses and income items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities. |
|
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. |
|
us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:Assets |
xbrli:monetaryItemType |
| Instant |
| Debit |
| |
|
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. |
|
us-gaap:AssetsAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:AssetsCurrent |
xbrli:monetaryItemType |
| Instant |
| Debit |
| |
|
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. |
|
us-gaap:AssetsCurrentAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:BasisOfAccounting |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). |
|
us-gaap:Cash |
xbrli:monetaryItemType |
| Instant |
| Debit |
| |
|
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. |
|
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes. |
|
us-gaap:CashAndCashEquivalentsPolicyTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. |
|
us-gaap:CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:CommonStockMember |
nonnum:domainItemType |
| Duration |
| |
| |
|
Stock that is subordinate to all other stock of the issuer. |
|
us-gaap:CommonStockParOrStatedValuePerShare |
num:perShareItemType |
| Instant |
| |
| |
|
Face amount or stated value per share of common stock. |
|
us-gaap:CommonStockSharesAuthorized |
xbrli:sharesItemType |
| Instant |
| |
| |
|
The maximum number of common shares permitted to be issued by an entity's charter and bylaws. |
|
us-gaap:CommonStockSharesIssued |
xbrli:sharesItemType |
| Instant |
| |
| |
|
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. |
|
us-gaap:ComprehensiveIncomeNetOfTax |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
|
us-gaap:ConcentrationRiskCreditRisk |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy for credit risk. |
|
us-gaap:ConsolidationPolicyTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. |
|
us-gaap:CostOfGoodsSold |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
Total costs related to goods produced and sold during the reporting period. |
|
us-gaap:CumulativeEarningsDeficit |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
Amount of cumulative earnings (deficits) for relevant time periods. |
|
us-gaap:DebtDisclosureTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. |
|
us-gaap:Deposits |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others. |
|
us-gaap:Depreciation |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. |
|
us-gaap:DepreciationAndAmortization |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. |
|
us-gaap:EarningsPerSharePolicyTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. |
|
us-gaap:EmployeeBenefitsAndShareBasedCompensation |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit. |
|
us-gaap:EquityComponentDomain |
nonnum:domainItemType |
| Duration |
| |
| |
|
Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc. |
|
us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. |
|
us-gaap:GrossProfit |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. |
|
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations. |
|
us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare |
num:perShareItemType |
| Duration |
| |
| |
|
The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares. |
|
us-gaap:IncomeStatementAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:IncomeTaxDisclosureTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. |
|
us-gaap:IncomeTaxesPaid |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income. |
|
us-gaap:IncomeTaxesPaidNet |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes. |
|
us-gaap:IncreaseDecreaseInAccountsPayable |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
|
us-gaap:IncreaseDecreaseInAccountsReceivable |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
|
us-gaap:IncreaseDecreaseInAccruedLiabilities |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
|
us-gaap:IncreaseDecreaseInDeposits |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances. |
|
us-gaap:IncreaseDecreaseInInventories |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
|
us-gaap:IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:IncreaseDecreaseInPrepaidExpense |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. |
|
us-gaap:InterestAndDividendIncomeOperating |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein. |
|
us-gaap:InterestPaid |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
The amount of cash paid for interest during the period. |
|
us-gaap:InventoryGross |
xbrli:monetaryItemType |
| Instant |
| Debit |
| |
|
Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. |
|
us-gaap:InventoryPolicyTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory. |
|
us-gaap:LiabilitiesAndStockholdersEquity |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
|
us-gaap:LiabilitiesAndStockholdersEquityAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:LiabilitiesCurrent |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
|
us-gaap:LiabilitiesCurrentAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:LiquidityDisclosureTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substa |
|
us-gaap:LongTermDebtAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:LongTermDebtNoncurrent |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations. |
|
us-gaap:NetCashProvidedByUsedInContinuingOperations |
xbrli:monetaryItemType |
| Duration |
| |
| |
|
The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label. |
|
us-gaap:NetCashProvidedByUsedInFinancingActivities |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
|
us-gaap:NetCashProvidedByUsedInFinancingActivitiesAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:NetCashProvidedByUsedInInvestingActivities |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
|
us-gaap:NetCashProvidedByUsedInInvestingActivitiesAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:NetCashProvidedByUsedInOperatingActivitiesAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:NetIncomeLoss |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
|
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period). |
|
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions. |
|
us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items. |
|
us-gaap:NotesPayable |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. |
|
us-gaap:OperatingExpenses |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
|
us-gaap:OperatingExpensesAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. |
|
us-gaap:OtherAssets |
xbrli:monetaryItemType |
| Instant |
| Debit |
| |
|
The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet. |
|
us-gaap:OtherAssetsAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:OtherIncomeAndExpensesAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:PaymentsOfStockIssuanceCosts |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
The cash outflow for cost incurred directly with the issuance of an equity security. |
|
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
|
us-gaap:PolicyLoansReceivablePolicy |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy for policy loans receivable, including the basis for determining the amount reported for loans made to policyholders against and secured by future policy benefits. May also disclose the range of interest rates charged to policyholders on such loans. |
|
us-gaap:PrepaidExpenseCurrent |
xbrli:monetaryItemType |
| Instant |
| Debit |
| |
|
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. |
|
us-gaap:ProceedsFromIssuanceOrSaleOfEquity |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. |
|
us-gaap:ProceedsFromNotesPayable |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
The cash inflow from a borrowing supported by a written promise to pay an obligation. |
|
us-gaap:PropertyPlantAndEquipmentAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:PropertyPlantAndEquipmentNet |
xbrli:monetaryItemType |
| Instant |
| Debit |
| |
|
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
|
us-gaap:PropertyPlantAndEquipmentOther |
xbrli:monetaryItemType |
| Instant |
| Debit |
| |
|
Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale. |
|
us-gaap:PropertyPlantAndEquipmentPolicyTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments. |
|
us-gaap:PropertyPlantAndEquipmentScheduleOfSignificantAcquisitionsAndDisposalsTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Tabular disclosure of all information related to any significant acquisition and disposal. Disclosure may include methodology and assumptions, type of asset, asset classification, useful life, useful purpose, acquisition cost, method of acquisition or disposal, depreciation method, gain (loss) on disposal pretax and net of tax, date of acquisition or disposal and restrictions on amount of proceeds from donated assets. |
|
us-gaap:ResearchAndDevelopmentExpense |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. |
|
us-gaap:RetainedEarningsAccumulatedDeficit |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
The cumulative amount of the reporting entity's undistributed earnings or deficit. |
|
us-gaap:RetainedEarningsMember |
nonnum:domainItemType |
| Duration |
| |
| |
|
The cumulative amount of the reporting entity's undistributed earnings or deficit. |
|
us-gaap:RevenueRecognitionPolicyTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction. |
|
us-gaap:Revenues |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). |
|
us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. |
|
us-gaap:ScheduleOfDebtInstrumentsTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. |
|
us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. |
|
us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. |
|
us-gaap:SellingGeneralAndAdministrativeExpense |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
|
us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement. |
|
us-gaap:SharesIssued |
xbrli:sharesItemType |
| Instant |
| |
| |
|
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. |
|
us-gaap:SignificantAccountingPoliciesTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
The entire disclosure for all significant accounting policies of the reporting entity. |
|
us-gaap:StatementEquityComponentsAxis |
xbrli:stringItemType |
| Duration |
| |
| |
|
Information by component of equity. |
|
us-gaap:StatementOfCashFlowsAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:StatementOfFinancialPositionAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:StatementOfStockholdersEquityAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
xbrli:sharesItemType |
| Duration |
| |
| |
|
Number of shares issued during the period as a result of the conversion of convertible securities. |
|
us-gaap:StockIssuedDuringPeriodSharesNewIssues |
xbrli:sharesItemType |
| Duration |
| |
| |
|
Number of new stock issued during the period. |
|
us-gaap:StockIssuedDuringPeriodSharesOther |
xbrli:sharesItemType |
| Duration |
| |
| |
|
Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed. |
|
us-gaap:StockIssuedDuringPeriodValueNewIssues |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. |
|
us-gaap:StockIssuedDuringPeriodValueOther |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed. |
|
us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised |
xbrli:monetaryItemType |
| Duration |
| Credit |
| |
|
Value of stock issued as a result of the exercise of stock options. |
|
us-gaap:StockholdersEquity |
xbrli:monetaryItemType |
| Instant |
| Credit |
| |
|
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. |
|
us-gaap:StockholdersEquityAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:StockholdersEquityNoteDisclosureTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. |
|
us-gaap:StockholdersEquityOther |
xbrli:monetaryItemType |
| Duration |
| Debit |
| |
|
This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy. |
|
us-gaap:SubsequentEventsTextBlock |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. |
|
us-gaap:SupplementalCashFlowInformationAbstract |
xbrli:stringItemType |
| Duration |
| |
| |
|
|
|
us-gaap:UseOfEstimates |
nonnum:textBlockItemType |
| Duration |
| |
| |
|
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. |
|
us-gaap:WeightedAverageBasicSharesOutstandingProForma |
xbrli:sharesItemType |
| Duration |
| |
| |
|
The weighted average number of shares (units) outstanding in the calculation of pro forma basic earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering. |
|
Total Elements |
|
143 |
Total Non-Abstract Elements |
|
108 |
Total Extension Elements |
|
1 |
Percent Extended |
|
0% |
Percent Extended (excluding abstracts) |
|
0% |
|
(End Elements) |